FDA Chalks Up Pradaxa Safety Scare To “Stimulated Reporting”
This article was originally published in The Pink Sheet Daily
Executive Summary
In a New England Journal of Medicine editorial, FDA officials stress value and safety of Boehringer Ingelheim’s novel anticoagulant Pradaxa, which is struggling amid highly publicized reports of bleeding.